#ADA26: Pfizer's monthly shot shows effect on obesity, diabetes

June 6, 2026 09:00 AM EDT R&DPharmaManufacturing Pfiz­er's good-enough obe­si­ty da­ta in a crowd­ed mar­ket may force com­pe­ti­tion on price, dos­ing Elizabeth Cairns Senior biopharma journalist The long-act­ing GLP-1 shot that was the cen­ter­piece of Pfiz­er’s ac­qui­si­tion of Met­sera last year looks ef­fec­tive in pa­tients with both obe­si­ty and di­a­betes, ac­cord­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER